Adam K. Simpson - 22 Jan 2024 Form 4 Insider Report for Icosavax, Inc.

Role
Chief Executive Officer, Director
Signature
/s/ Elizabeth Bekiroglu, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
22 Jan 2024
Net transactions value
+$100,979
Form type
4
Filing time
23 Jan 2024, 18:15:19 UTC
Previous filing
04 Jan 2024
Next filing
02 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ICVX Common Stock Options Exercise $4,023 +4,789 +1.8% $0.8400* 265,430 22 Jan 2024 Direct
transaction ICVX Common Stock Options Exercise $96,956 +93,227 +35% $1.04* 358,657 22 Jan 2024 Direct
holding ICVX Common Stock 531,576 22 Jan 2024 By family trust
holding ICVX Common Stock 129,032 22 Jan 2024 By family trust
holding ICVX Common Stock 129,032 22 Jan 2024 By family trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ICVX Stock Option (Right to Buy) Options Exercise $0 -4,789 -100% $0.000000* 0 22 Jan 2024 Common Stock 4,789 $0.8400 Direct F1
transaction ICVX Stock Option (Right to Buy) Options Exercise $0 -93,227 -31% $0.000000 206,449 22 Jan 2024 Common Stock 93,227 $1.04 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option vested on February 21, 2021, and 1/48th of the shares subject to the option vest monthly thereafter.
F2 25% of the shares subject to the option vested on January 14, 2022, and 1/48th of the shares subject to the option vest monthly thereafter.